Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1248.65
₹7.90(0.63%)
At close: 4:00 PM EDT
₹1248.65
₹7.90(0.63%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹1,800.00
Previous CloseN/A
Volume79.36K
Average Volume (3M)12.81K
Market Cap
₹148.59B
Enterprise Value₹101.96K
Total Cash (Recent Filing)₹4.16B
Total Debt (Recent Filing)₹23.16M
Price to Earnings (P/E)54.1
Beta1.21
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.53%
Share Statistics
EPS (TTM)24.86
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.76
Revenue Forecast (FY)₹12.60B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExceptionally low leverage and steadily rising equity reduce financial distress risk and preserve strategic optionality. Over a multi-month horizon this supports funding for capacity, regulatory compliance and selective M&A or partnerships without pressure to cut R&D or production spending.
Consistent Cash GenerationReliable operating cash flow that typically exceeds net income underpins durable earnings quality and funds reinvestment. The 2026 FCF rebound shows capacity to self-fund capex and working capital needs, supporting steady API production and regulatory investments over months.
Specialized Fermentation API ExpertiseDeep fermentation capabilities and focus on complex APIs create technical barriers and stickier customer relationships. This niche positioning supports durable revenue streams from regulated export markets and long-term supply contracts with pharma formulators over the coming quarters.
Bears Say
Recent Revenue DeclineA reversal to negative top-line growth signals demand or contract timing weakness and increases execution risk. If underlying sales drivers do not recover, slower revenue growth can pressure reinvestment capacity and make margin sustainability harder to maintain over several quarters.
Margin Compression From Prior PeaksEroding margins versus peak years reduce excess profitability that funds R&D, capacity and resilience to pricing pressure. Sustained margin compression would lower free cash flow cushion and constrain capital deployment options over the medium term.
Volatile Free Cash Flow HistoryIntermittent negative FCF and variability indicate sensitivity to capex or working capital swings. Continued volatility can limit predictable reinvestment, raise funding needs in down cycles, and complicate long-term planning for capacity or regulatory compliance.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹1800.00 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹148.59B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 102 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Jul 31, 2026. The company reported ₹5.6 earnings per share for the quarter, missing the consensus estimate of ₹7.333 by -₹1.733.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Annually dividend of ₹7.55 which represents an annual dividend yield of 0.53%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹5.6 in its last earnings report, missing expectations of ₹7.333. Following the earnings report the stock price went up 6.533%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―
Anthem Biosciences Limited
―